Bayer, J&J Secure Win in Xarelto Patent Battle Over Generics

A patent on the blood-thinning drug Xarelto is valid, giving Johnson & Johnson and Bayer AG a win in their effort to delay generic competition to the lucrative product.

Mylan NV and Sigmapharm Laboratories LLC failed to prove the patent shouldn’t have been issued, Judge Lawrence Stengel of the U.S. District Court for the District of Delaware ruled July 13. The generic drug companies, who are looking to sell low-cost versions of the drug, had conceded they infringed U.S. Patent No. 7,157,456, which expires in August 2024, according to the FDA Orange Book listing for Xarelto.

Xarelto (rivaroxaban) is ...